Reddy Maya, Fenn Sarah, Rolnik Daniel Lorber, Mol Ben Willem, da Silva Costa Fabricio, Wallace Euan M, Palmer Kirsten R
Ritchie Centre, Department of Obstetrics and Gynaecology, School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia; Monash Women's, Monash Health, Melbourne, Victoria, Australia.
Ritchie Centre, Department of Obstetrics and Gynaecology, School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia.
Am J Obstet Gynecol. 2021 Feb;224(2):217.e1-217.e11. doi: 10.1016/j.ajog.2020.08.019. Epub 2020 Aug 12.
The diagnostic criteria for preeclampsia have evolved from the traditional definition of de novo hypertension and proteinuria to a broader definition of hypertension with evidence of end-organ dysfunction. Although this change is endorsed by various societies such as the International Society for the Study of Hypertension in Pregnancy and the American College of Obstetricians and Gynecologists, there remains controversy with regard to the implementation of broader definitions and the most appropriate definition of end-organ dysfunction.
This study aimed to assess the impact of different diagnostic criteria for preeclampsia on rates of disease diagnosis, disease severity, and adverse outcomes and to identify associations between each component of the different diagnostic criteria and adverse pregnancy outcomes.
We performed a retrospective cohort study of singleton pregnancies at Monash Health between January 1, 2016 and July 31, 2018. Within this population, all cases of gestational hypertension and preeclampsia were reclassified according to the International Society for the Study of Hypertension in Pregnancy 2001, American College of Obstetricians and Gynecologists 2018, and International Society for the Study of Hypertension in Pregnancy 2018 criteria. Differences in incidence of preeclampsia and maternal and perinatal outcomes were compared between the International Society for the Study of Hypertension in Pregnancy 2001 group and the extra cases identified by American College of Obstetricians and Gynecologists 2018 and International Society for the Study of Hypertension in Pregnancy 2018. Outcomes assessed included biochemical markers of preeclampsia, a composite of adverse maternal outcomes, and a composite of adverse perinatal outcomes. Multiple logistic regression analysis was also performed to assess each component of the American College of Obstetricians and Gynecologists 2018 and International Society for the Study of Hypertension in Pregnancy 2018 criteria and their associations with adverse maternal and perinatal outcomes.
Of 22,094 pregnancies, 751 (3.4%) women had preeclampsia as defined by any of the 3 criteria. Compared with International Society for the Study of Hypertension in Pregnancy 2001, the American College of Obstetricians and Gynecologists 2018 criteria identified an extra 42 women (n=654 vs n=696, 6.4% relative increase) with preeclampsia, and International Society for the Study of Hypertension in Pregnancy 2018 identified an extra 97 women (n=654 vs n=751, 14.8% relative increase). The additional women identified by International Society for the Study of Hypertension in Pregnancy 2018 exhibited a milder form of disease with lower rates of severe hypertension (62.4% vs 44.3%; P<.01) and magnesium sulfate use (11.9% vs 4.1%; P<.05) and a trend toward lower rates of adverse maternal outcomes (9.8% vs 4.1%). These women also delivered at a later gestation, and their babies had a lower number of neonatal intensive care unit admissions and adverse perinatal outcomes. Objective features such as fetal growth restriction, thrombocytopenia, renal and liver impairment, and proteinuria were associated with an increased risk of adverse maternal and perinatal outcomes, whereas subjective neurologic features demonstrated poorer associations.
Implementation of broader definitions of preeclampsia will result in an increased incidence of disease diagnosis. However, because women who exclusively fulfill the new criteria have a milder phenotype of the disease, it remains uncertain whether this will translate to improved outcomes.
子痫前期的诊断标准已从传统的新发高血压和蛋白尿定义演变为更广泛的高血压定义,并伴有器官功能障碍的证据。尽管这一变化得到了国际妊娠高血压研究学会和美国妇产科医师学会等多个学会的认可,但在更广泛定义的实施以及器官功能障碍的最恰当定义方面仍存在争议。
本研究旨在评估子痫前期不同诊断标准对疾病诊断率、疾病严重程度和不良结局的影响,并确定不同诊断标准的各个组成部分与不良妊娠结局之间的关联。
我们对2016年1月1日至2018年7月31日在莫纳什医疗中心的单胎妊娠进行了一项回顾性队列研究。在该人群中,所有妊娠期高血压和子痫前期病例均根据国际妊娠高血压研究学会2001年、美国妇产科医师学会2018年以及国际妊娠高血压研究学会2018年的标准进行重新分类。比较了国际妊娠高血压研究学会2001年组与美国妇产科医师学会2018年和国际妊娠高血压研究学会2018年确定的额外病例之间子痫前期发病率以及孕产妇和围产儿结局的差异。评估的结局包括子痫前期的生化标志物、孕产妇不良结局的综合指标以及围产儿不良结局的综合指标。还进行了多因素逻辑回归分析,以评估美国妇产科医师学会2018年和国际妊娠高血压研究学会2018年标准的各个组成部分及其与孕产妇和围产儿不良结局的关联。
在22094例妊娠中,751例(3.4%)妇女符合3种标准中任何一种定义的子痫前期。与国际妊娠高血压研究学会2001年标准相比,美国妇产科医师学会2018年标准多识别出42例子痫前期妇女(654例对696例,相对增加6.4%),国际妊娠高血压研究学会2018年标准多识别出97例子痫前期妇女(654例对751例,相对增加14.8%)。国际妊娠高血压研究学会2018年标准多识别出的妇女疾病表现较轻,重度高血压发生率较低(62.4%对44.3%;P<0.01),硫酸镁使用率较低(11.9%对4.1%;P<0.05),孕产妇不良结局发生率有降低趋势(9.8%对4.1%)。这些妇女分娩孕周较晚,其婴儿入住新生儿重症监护病房的次数和围产儿不良结局较少。胎儿生长受限、血小板减少、肾和肝功能损害以及蛋白尿等客观特征与孕产妇和围产儿不良结局风险增加相关,而主观神经学特征的关联性较差。
采用更广泛的子痫前期定义会导致疾病诊断率增加。然而,由于仅符合新标准的妇女疾病表型较轻,这是否会转化为更好的结局仍不确定。